Literature DB >> 8129437

Chemoprophylaxis for pulmonary aspergillosis during intensive chemotherapy.

F Cowie1, S T Meller, P Cushing, R Pinkerton.   

Abstract

Three children who developed pulmonary aspergillosis while being treated for leukaemia or non-Hodgkin's lymphoma. Each child continued with intensive myelosuppressive chemotherapy regimens during the infection and each was successfully treated with antifungal prophylaxis based on itraconazole by mouth. Amphotericin B was also given during periods of severe neutropenia. No reactivation of the fungal infection was seen.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8129437      PMCID: PMC1029718          DOI: 10.1136/adc.70.2.136

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  17 in total

1.  Invasive pulmonary aspergillosis in adult acute leukemia: clinical clues to its diagnosis.

Authors:  S L Gerson; G H Talbot; E Lusk; S Hurwitz; B L Strom; P A Cassileth
Journal:  J Clin Oncol       Date:  1985-08       Impact factor: 44.544

2.  Protective environment for marrow transplant recipients: a prospective study.

Authors:  C D Buckner; R A Clift; J E Sanders; J D Meyers; G W Counts; V T Farewell; E D Thomas
Journal:  Ann Intern Med       Date:  1978-12       Impact factor: 25.391

3.  Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies.

Authors:  G Tricot; E Joosten; M A Boogaerts; J Vande Pitte; G Cauwenbergh
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

4.  Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans.

Authors:  R Negroni; O Palmieri; F Koren; I N Tiraboschi; R L Galimberti
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

5.  Itraconazole in the treatment of human mycoses: review of three years of clinical experience.

Authors:  G Cauwenbergh; P De Doncker; K Stoops; A M De Dier; H Goyvaerts; V Schuermans
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

6.  Favorable outcome of invasive aspergillosis in patients with acute leukemia.

Authors:  P A Burch; J E Karp; W G Merz; J E Kuhlman; E K Fishman
Journal:  J Clin Oncol       Date:  1987-12       Impact factor: 44.544

7.  An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis.

Authors:  J E Karp; P A Burch; W G Merz
Journal:  Am J Med       Date:  1988-08       Impact factor: 4.965

8.  Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy.

Authors:  M J Robertson; R A Larson
Journal:  Am J Med       Date:  1988-02       Impact factor: 4.965

9.  Fungal infections in patients with acute leukemia.

Authors:  M W DeGregorio; W M Lee; C A Linker; R A Jacobs; C A Ries
Journal:  Am J Med       Date:  1982-10       Impact factor: 4.965

10.  Problems of infection after bone marrow transplantation.

Authors:  J G Watson
Journal:  J Clin Pathol       Date:  1983-06       Impact factor: 3.411

View more
  4 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

Review 2.  Practical modalities for prevention of fungal infections in cancer patients.

Authors:  B E De Pauw
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

3.  Risk factors for systemic fungal infections in liver transplant recipients.

Authors:  J Briegel; H Forst; B Spill; A Haas; B Grabein; M Haller; E Kilger; K W Jauch; K Maag; G Ruckdeschel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

4.  Long term outcome of medical and surgical co-management of craniospinal aspergillosis in an immunocompromised patient.

Authors:  Dipu Sathyapalan; Sabarish Balachandran; Anil Kumar; Bindu Mangalath Rajamma; Ashok Pillai; Vidya P Menon
Journal:  Med Mycol Case Rep       Date:  2016-11-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.